Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer by Culjkovic, Biljana & Borden, Katherine L.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2009, Article ID 981679, 12 pages
doi:10.1155/2009/981679
Review Article
UnderstandingandTargeting the EukaryoticTranslation
Initiation Factor eIF4E in Head and Neck Cancer
BiljanaCuljkovicandKatherine L. Borden
Institute for Research in Immunology and Cancer and Department of Pathology and Cell Biology, Universit´ ed eM o n t r ´ eal,
Montreal, QC, Canada H4M 1J6
Correspondence should be addressed to Katherine L. Borden, katherine.borden@umontreal.ca
Received 1 March 2009; Accepted 30 September 2009
Recommended by Amanda Psyrri
The eukaryotic translation initiation factor eIF4E is elevated in about 30% of human malignancies including HNSCC where its
levels correlate with poor prognosis. Here, we discuss the biochemical and molecular underpinnings of the oncogenic potential
of eIF4E. Studies in human leukemia specimens, and later in a mouse model of prostate cancer, strongly suggest that cells with
elevated eIF4E develop an oncogene dependency to it, making them more sensitive to targeting eIF4E than normal cells. We
describe several strategies that have been suggested for eIF4E targeting in the clinic: the use of a small molecule antagonist of
eIF4E (ribavirin), siRNA or antisense oligonucleotide strategies, suicide gene therapy, and the use of a tissue-targeting 4EBP
fusion peptide. The ﬁrst clinical trial targeting eIF4E indicates that ribavirin eﬀectively targets eIF4E in poor prognosis leukemia
patients and more importantly leads to striking clinical responses including complete and partial remissions. Finally, we discuss
the relevance of these ﬁndings to HNSCC.
Copyright © 2009 B. Culjkovic and K. L. Borden. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. GeneralizedRole for eIF4E in Cancer
The eukaryotic translation initiation factor 4E (eIF4E) is a
protein that plays a central role in the regulation of gene
expressionattheposttranscriptional level.eIF4Ebindsthe7-
methyl guanosine “m7G cap” structure found on the 5  end
of mRNAs. In the cytoplasm, eIF4E catalyses cap-dependent
protein synthesis [1, 2]. Importantly, eIF4E eﬀects the
translation of some mRNAs, known as eIF4E sensitive, more
than other transcripts. For instance, elevated eIF4E levels
selectivelyincreasetranslationofmRNAscodingforavariety
of potent growth stimulatory proteins such as VEGF, Pim-1,
and ornithine decarboxylase (ODC) [3–5]. In the nucleus,
eIF4E mediates in the export of another subset of mRNAs
(such as cyclin D1 and ODC mRNAs) to the cytoplasm
[5–7]. Thus eIF4E can modulate gene expression at two
levels: by exporting mRNAs to the cytoplasm increasing their
concentration therein and by enhancing the translational
eﬃciency of transcripts that are already in the cytoplasm.
Not all transcripts are aﬀected at both levels. Importantly,
eIF4E requires its m7G cap binding function in order to act
in either of these functions. Clearly, dysregulation of eIF4E
will profoundly aﬀect the cellular proteome.
The process of malignant transformation requires multi-
ple molecular events involving activation of proto-oncogene
products that stimulate growth and inactivation of suppres-
sor genes that inhibit cellular proliferation. Together, these
eventsresultinselectivedysregulationofcellularmetabolism
and growth. Critical control points in the cell cycle, DNA
replication, and protein synthesis are just a few of many
potential sites where alterations of normal functions may
result in tumorigenesis. Because the overexpression of eIF4E
results in the upregulation of multiple gene products that
play critical roles in cycle progression and survival, it is not
surprising that the elevation of eIF4E has been detected in
various malignancies [3].
eIF4E is overexpressed in many epithelial cell cancers,
including breast [8–12], colon [13, 14], bladder [15–19],
cervix [20, 21], lung [22–24], and squamous cell carcinoma
oftheheadandneck[25–32].SomestudiesreportthateIF4E
is overexpressed in almost 100% of tumors of the breast,
head and neck, and colon [8, 27, 32]. Several retrospective2 Journal of Oncology
studies indicate that eIF4E elevation is correlated with poor
prognosis. As discussed below, high eIF4E levels in the
HNSCC correlated with higher incidence of relapse [26–
29, 32]. eIF4E overexpression was detected at a range of 3–
30 fold in breast carcinomas, compared to normal breast
tissue [8, 10], and eIF4E levels were signiﬁcantly increased in
vascularized malignant ductules of invasive carcinomas [33].
BreastcancerpatientswithhigheIF4Eexpression(>7-foldto
normal) experienced a statistically signiﬁcant poorer clinical
outcome with a higher risk for recurrence and cancer related
death [11]. Further, increased levels of eIF4E are observed
in non-Hodgkin’s lymphomas but not in benign lesions
[34, 35]. Here, eIF4E levels correlated with the aggressiveness
of these lesions [34, 35]. In prostate cancer, eIF4E levels were
also correlated with worse prognosis [36]. In acute myeloid
leukemia (AML), elevated eIF4E levels are characteristic of
the poor prognosis M4 and M5 AML subtypes [37].
Given that both normal and cancer cells express eIF4E,
it is important to develop therapeutic strategies that target
cancer cells without harming normal cells. There is evidence
that cancer cells have developed an oncogene addiction to,
or dependency on, eIF4E. In studies in primary human
leukemia specimens, subtypes of leukemias with elevated
levels of eIF4E are sensitive to inhibition of eIF4E by
antagonists at levels 100-fold less than those that eﬀect
normal bone marrow or other leukemic subtypes [38]. More
recent studies suggest a similar case in a prostate cancer
mouse model [39].
In animal models, eIF4E overexpression is correlated
with not only increased numbers of tumors but also
increased invasion, metastases, and angiogenesis [3, 15, 40].
Mice with transgene overexpression of eIF4E developed a
variety of cancers of distinct histological origin [41]. These
cancers develop despite the fact that the level of eIF4E
overexpression in these mice is much less than the corre-
sponding levels of eIF4E overexpression found in patients
[32, 33, 37]. Further, a lymphoma mouse model showed that
eIF4Eoverexpressingmicedevelopedmorelymphomas[42].
2.DysregulationofeIF4EinHNSCC
eIF4E is found to be elevated in the vast majority (in
some studies even 100% of cases) of HNSCC specimens,
with levels being 3 to 24 fold elevated relative to normal
controls [26–30, 32]. High eIF4E levels in surgical margins
are predictive of increased risk of recurrence in HNSCC
[26–29]. Overexpression of eIF4E in >5% of the basal layer
of histologically tumor-free surgical margins of HNSCC
patients predicted a signiﬁcantly increased risk of recurrence
[27]. This prediction is important for patient outcome as
most HNSCC patients will succumb due to local recurrence
[26, 28, 29]. It has been demonstrated that eIF4E overex-
pression is associated with eIF4E gene ampliﬁcation in both
HNSCC and in breast carcinomas [30, 43–45]. An increased
level of eIF4E gene ampliﬁcation was observed when benign
tumors and invasive carcinomas of the head and neck were
compared. Benign tumors only had moderate evidence for
gene ampliﬁcation, while malignant tumors had a 4–15 fold
level of ampliﬁcation [43]. eIF4E protein levels were elevated
in premalignant lesions in the larynx, but to a lesser extent
than observed in HNSCC [25]. These studies suggest that
progression to the malignant phenotype paralleled eIF4E
gene ampliﬁcation and overexpression [43]. Also, there was a
progressiveincreaseinthedegreeofeIF4Egeneampliﬁcation
andproteinexpressionwhencomparisonsweremadeamong
samples from tumor free margins of resected carcinoma
specimens, tumor free regions adjacent to tumor core and
tumor core samples [44]. This suggests that molecular
events such as eIF4E gene ampliﬁcation may precede cellular
morphological changes, and that surgical margins which
appear tumor free microscopically, may have elevated eIF4E
protein levels. Thus, eIF4E levels could be used as a marker
for prediction of early recurrence. It has been postulated
that somewhere in the multistep pathway of carcinogenesis,
elevation of eIF4E is a necessary event in progression of
most solid tumors, and that eIF4E does not only reﬂect the
proliferativestatusofcellsbutalsotheirmalignantproperties
[28, 46].
Consistent with their derivation from hypopharyngeal
squamous carcinoma, FaDu cells [48] have elevated eIF4E
[49] ,a n da ss e e ni nm a n yc e l lt y p e s ,e I F 4 Ei sf o u n di nb o t h
the nucleus and cytoplasm (Figure 1). Further, eIF4E levels
a r ee l e v a t e di nF a D uc e l l sd u et ob o t hg e n ea m p l i ﬁ c a t i o n ,
and increased mRNA stability [50]. Thus, there appears to
be multiple ways to elevate eIF4E levels (see below).
3. Biochemical Underpinningsof
eIF4E’s Biological Effects
eIF4E overexpression profoundly alters the cellular pro-
teome. However, experiments as early as 1980 [51]a n d
more recent studies using knockdown strategies indicate
that alterations in eIF4E expression do not uniformly alter
the proteome [3, 5, 52–57]. In other words, the expression
o fs o m eg e n e si sm o r ea ﬀected by modulation of eIF4E
levels. These genes are referred to as eIF4E sensitive. In
the cytoplasm, eIF4E recruits the transcript to the ribo-
some thereby increasing its translational eﬃciency. When
eIF4E is overexpressed, sensitive transcripts have a higher
ribosomes/mRNA ratio enabling more eﬃcient translation
without modulating mRNA levels in the cytoplasm. Notably,
sensitivemRNAshavemorehighlystructured5  UTRsversus
insensitive housekeeping mRNAs such as GAPDH or β-
actin which contain short, unstructured 5  UTRs [3, 52, 58].
Transcripts controlled at this levels often code for proteins
involved in proliferation such as c-Myc, Pim 1, VEGF, and
ODC [4, 5, 55, 59].
Up to 68% of eIF4E is found in the nucleus of cells
from a wide variety of species ranging from yeast to humans
[7, 60–63]. These include FaDu cells, which have high eIF4E
levels relative to normal cells and have eIF4E in both the
nucleus and cytoplasm (Figure 1). As in the cytoplasm,
only a subset of transcripts is sensitive to eIF4E dependant
mRNA export [5]. These mRNAs contain a discrete 50
nucleotide element in their 3 UTR known as the eIF4E
sensitivity element (4E-SE) [6, 64, 65]. Removal of the 4E-SEJournal of Oncology 3
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Figure1:FaDucellsimmunostainedforeIF4Eshowingcytoplasmicandnuclearlocalization.CellswerestainedusingeIF4EmAbconjugated
directly to FITC (green) and nuclear marker DAPI (blue) as described [37, 47]. Micrographs were collected on laser scanning confocal
microscope using 100X objective and 2x digital zoom.
ablates eIF4E sensitivity [65]. Many mRNAs sensitive to
eIF4E at the export level code for proteins that promote
proliferationandsurvival.Increasedexportofthetranscripts
leads to increased levels of the mRNA available to the
translationmachinery,withoutalteringtranslationeﬃciency
[5]. In the nucleus, eIF4E is found in the nucleoplasm, in
nuclear bodies co-localising with 4E-SE containing mRNAs
or colocalising with promyelocytic leukaemia (PML) nuclear
bodies (with no RNA). PML is a potent inhibitor of its
mRNA export function and a potent inhibitor of eIF4E
mediated transformation [47, 60, 66, 67].
Regulation of transcripts by eIF4E can occur at the
mRNA export level, the translation level, or both (Figure 2).
For instance, cyclin D1 transcripts are only sensitive to eIF4E
at the mRNA export level [5, 60, 61, 65]. VEGF transcripts
areonlysensitivetoeIF4Eattheleveloftranslation[5,58].In
contrast, ODC transcripts are sensitive to eIF4E at both the
mRNA export and translation levels [5]. ODC is regulated
at both levels because it contains both the complex 5 UTR
sensitising it to translation and the 4E-SE in its 3 UTR
sensitisingittoeIF4EdependentmRNAexport.Importantly,
4E-SEcontainingmRNAsisexportedthroughapathwaythat
is distinct from bulk mRNA export [64]. Unlike bulk mRNA
export which is TAP/NXF1 dependent, eIF4E dependent
mRNA export is CRM1 dependent and requires the 4E-SE
and the mRNA export factor LRPPRC [64, 68].
The combinatorial eﬀects that eIF4E have on gene
expression position it as a central node in an RNA regulon
governing proliferation and cell survival [64, 65]. The
RNA regulon is a theoretical construct that outlines a
means by which posttranscriptional gene expression can be
coordinated [69, 70]. In this model, elements in the UTRs
of transcripts sensitise groups of transcripts to the same
level of regulation. Transcripts with the same combination
of elements, known as USER codes, will be coregulated. In
this way, transcripts coding for proteins acting in the same
biochemical pathway can have their production coordinated
and thus the biochemical output of the pathway optimised.
InthecaseofeIF4E,thecomplex5 UTRandthe4E-SEinthe
3 UTR can be considered to be USER codes for translation
and export, respectively [6].
An example of the RNA regulon is the ability of eIF4E to
modulateAktsignalling.eIF4Eoverexpression,viaitsmRNA
export function, upregulates the expression of an activator of
Akt, NBS1 [71, 72]. Furthermore, it enhances the expression
of several downstream eﬀectors of Akt including c-myc,
cyclin D1, and cyclin E1 [5, 64]. eIF4E rescues serum-starved
ﬁbroblasts from serum-induced apoptosis. However, eIF4E
loses this activity in Akt1−/− cells whereas reintroduction
of Akt1 enables eIF4E to rescue the cells again [71]. Thus,
through the coordinated regulation of genes involved in the
Akt pathway, eIF4E can promote cellular survival. These
observations are particularly interesting in the context of
HNSCC progression. In a study of HNSCC tumors and
surgical margins, elevated levels of eIF4E correlated with
elevated Akt activation [73].
In summary, eIF4E modulates gene expression at two
levels: mRNA export and translation. These functions are
coordinated through the RNA regulon. In many cases, eIF4E
sensitive mRNAs act in the same biochemical pathways
such as cell cycle progression or survival pathways. This
coordination potently drives the oncogenic potential of
eIF4E [6].
4. Molecular Basis for
eIF4E Mediated Transformation
eIF4E overexpression leads to transformation in cell culture,
as well as in animal models, as described above. Speciﬁcally,
eIF4E overexpression leads to loss of contact inhibition of
ﬁbroblasts, growth in soft agar and increased proliferation
[47, 58, 61, 74–76]. eIF4E overexpression rescues cells from
certain types of apoptotic stimuli [77–81]. In ﬁbroblasts,
serum deprivation induced apoptotic rescue of eIF4E is Akt1
dependent [82]. Both the nuclear and cytoplasmic functions
of eIF4E contribute to its oncogenic potential [37, 47, 58, 60,
61]. For instance, a mutant of eIF4E, W73A, which acts in4 Journal of Oncology
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Figure 2: A diagram summarizing the nuclear and cytoplasmic functions of eIF4E. Some factors that directly regulate eIF4E functions and
proteins involved in regulation of eIF4E subcellular distribution are shown. Not all regulators are shown for the sake of clarity. mRNAs are
depicted as black lines with black balls denoting the 5 m7cap and with/without complex 5 UTRs shown in red and 4ESE element shown in
green.
mRNA export but is deﬁcient in promotion of translation,
acts in both transformation and survival to the same extent
as wild-type eIF4E [47, 60, 76].
5. RedundantRegulation of eIF4E
Regulators of eIF4E functions are positioned to modulate
the eIF4E regulon, co-ordinately modulating cell cycle
progression, and cell survival (Figure 2). One of the best-
characterized regulators of eIF4E is eIF4E binding protein
1 (BP1) [58, 83]. This protein uses a conserved eIF4E
binding site to associate with eIF4E, and thereby precludes
access of eIF4E to eIF4G and the rest of the translation
machinery [58]. This binding site is deﬁned as follows:
YXXXXLφ (where X is any residue and φ is a hydrophobic
residue). Studies suggest that BP1 increases cap aﬃnity and
thereby sequesters both eIF4E and the RNA in question
from the translational machinery [1]. The association of
BP1 with eIF4E is modulated by phosphorylation of BP1
[58, 83]. Phosphorylation of BP1 leads to a reduction in its
interaction with eIF4E and thereby and results in increased
translational activity of eIF4E. Phosphorylation is mTOR
dependent and thus rapamycin treatment leads to reduced
phosphorylation of BP1, increasing its association with
eIF4E and thereby reducing translation of eIF4E sensitive
mRNAs [84]. In contrast to eIF4E, BP1 overexpression
sensitizes Ras transformed cells to apoptosis when treated
with certain cytostatic drugs [85]. In addition, BP1 overex-
pression represses eIF4E mediated transformation of NIH
3T3 cells [58]. However, BP1−/− and BP1−/− BP2−/− mice
do not develop cancers more readily than controls [86–89],
highlighting the importance of redundancy of regulators
in the control of eIF4E. Studies on BP1 in the literature
focus on BP1 as a regulator of the cytoplasmic functions of
eIF4E [58, 84]. However, endogenous BP1 associates with
eIF4E in both the nuclear and cytoplasmic compartments
and thus likely modulates eIF4E activity at both the level of
translation andmRNA export (see[90] and ourunpublished
observations).
Counter-intuitively, BP1 levels are elevated in prostate
and breast cancer and these levels correlate with a more
advanced stage [91]. In esophageal cancers, there are more
BP1-eIF4E complexes than in normal tissues, further com-
plicatingtheacceptedmodelofBP1regulationofeIF4E[92].
Clearly, there is much more to be understood about BP1 and
its implications for eIF4E activity.
There are many other regulators of eIF4E. The vast
majority of these regulators contain the YXXXXLφ motif
like eIF4G and the BPs. These regulators include a set of
over 200 homeodomain proteins that contain this motif.
Some of these members are negative regulators of eIF4E,
such as PRH/Hex. PRH is a nuclear protein that impedes
eIF4E’s mRNA export function [76]. PRH overexpression
leads to the cytoplasmic redistribution of eIF4E [37, 76].
Other members of this group of homeodomain containing
regulators include Emx2, Otx, Engrailed 2, Hox11, Bicoid,
and HoxA9 [93]. HoxA9 can stimulate both the nuclear and
cytoplasmic functions of eIF4E [94]. Emx2 travels from one
neuron to another through the synapse enabling localized
translational control of eIF4E via signals to the adjacent
neuron. In this way, Emx2 controls eIF4E activity remotelyJournal of Oncology 5
[93]. Thus, eIF4E function can be regulated in a tissue and
context dependent manner.
There is also a discrete class of eIF4E regulators that
utilize a RING domain to impede eIF4E function. These
regulators include the promyelocytic leukemia protein PML,
HHARI, and arenaviral Z proteins from LCMV and Lassa
viruses [47, 60, 95]. PML and the Z proteins use their RING
motifs to associate with eIF4E and inhibit eIF4E function by
reducing the aﬃnity of eIF4E for the m7G cap by up to 100-
fold [28, 37, 96]. These were the ﬁrst proteins reported to
reduce the aﬃnity of eIF4E for the m7Gc a p .P M Li sak e y
cellular inhibitor of the oncogenic activities of eIF4E. The
abilitytoinhibit eIF4Efunctioniscloselytiedwiththeability
of PML to impair cap binding, and thus the mRNA export
activity of eIF4E [47, 64, 65, 71, 97]. Similarly, Z also impairs
eIF4E cap binding and function [97]. Notably, PML and Z
do not alter eIF4E levels, and therefore do not appear to
act directly or indirectly in its protein stability, unlike other
RINGs [97].
Clearly, the regulation of eIF4E activity is redundant and
multifactorial. There are tissue speciﬁc regulators such as the
homeodomainproteinsandmoreubiquitousregulatorssuch
asPMLandBP1(Figure 2).Redundancyofregulatorsisseen
for both the nuclear and cytoplasmic arms of eIF4E activity.
6. ControllingeIF4E Localization—a Key Step
inthe Regulation of eIF4E
Clearly, modulating the subcellular distribution of eIF4E will
have profound impacts on the sets of genes it regulates and
thus on its biological eﬀects. For instance, eIF4E localization
is substantially altered during Xenopus gastrulation [7]. Fur-
thermore, eIF4E nuclear-cytoplasmic localization changes
dramatically during diﬀerentiation of mouse embryonic
stemcellstomacrophages(KLBB,unpublishedobservation).
As discussed above, eIF4E is found in both the nuclear
and cytoplasmic compartments. Recent studies indicate that
withinthecytoplasm,eIF4Eisfoundnotonlyassociatedwith
actively translating transcripts, but also with cytoplasmic
structures known as processing bodies (P-bodies) [98, 99].
These structures contain a variety of factors including many
associated with RNA degradation as well as eIF4E [100].
RNAs associated with these structures are sequestered from
the translational machinery. It is thought that P-bodies are
a temporary storage depot for these RNAs while their fate
(in terms of degradation, sequestration, translation, etc.)
is being decided [100]. Thus, in the cytoplasm, eIF4E is
associated with both the translation machinery and in some
cases with mRNAs that are being sequestered from this
machinery(e.g.,inPbodies),perhapsleftthereuntilthetime
is right for these mRNAs to be translated.
Ultimately, the biochemical pathways in which eIF4E
functions (mRNA export, mRNA translation, or mRNA
sequestration) depend on the subcellular distribution of
eIF4E. Little is known about what regulates nuclear entry
of eIF4E and what determines which cytoplasmic compart-
ments in which eIF4E will be found. To date, the only factor
known to directly modulate the subcellular distribution of
eIF4E is the eIF4E transporter protein (4E-T) [98, 101]. 4E-
T uses its conserved eIF4E binding site to interact directly
withthedorsalsurfaceofeIF4E.Theoriginalstudysuggested
that 4E-T transported eIF4E protein into the nucleus [101].
However, several other studies, including subsequent studies
by the Sonenberg group [98], indicate that overexpression
of 4E-T leads to relocalization of the majority of nuclear
eIF4E to the cytoplasm, where a subset is found in P-bodies.
The molecular mechanism for this redistribution is not yet
known.
Other factors also modulate the subcellular distribution
of eIF4E, including BP1 [90], the proline rich homeodomain
protein PRH [37, 76], and the leucine rich protein LRPPRC
[68]( Figure 2). PRH is a potent inhibitor of the mRNA
export function of eIF4E [76]. PRH overexpression leads to
redistribution of nuclear eIF4E to the cytoplasm [37, 76].
LRPPRC overexpression leads to re-distribution of eIF4E
within the nucleus. Here, upon LRPPRC overexpression,
LRPPRC competes for PML leading to reduced PML-eIF4E
co-localization. This redistribution correlates with increased
eIF4E dependent mRNA export [68]. In summary, these
factors are positioned to impact the nuclear and cytoplasmic
arms of eIF4E activity and thus alter the eﬀects of eIF4E on
the proteome.
There are other means to modulate the subcellular
distribution of eIF4E. Interestingly, transduction of primary
leukemia specimens (M4/M5 AML) with the inhibitor of
NFκBa c t i v i t y ,I κB-SR, leads to a substantial re-organization
of eIF4E, reducing the amount of eIF4E found in the nuclear
fraction and increasing the amount in the cytoplasm, and
reorganization of the remaining eIF4E nuclear bodies into
structures which are morphologically indistinguishable from
normal cells [37, 93]. Thus, the subcellular distribution
of eIF4E appears linked to NFκB activity. As expected,
transduction of IκB-SR leads to reduced eIF4E dependent
mRNA export in these specimens [37, 93]. In this way, eIF4E
localization is linked to NFkB activity.
In addition, the subcellular distribution of eIF4E can
be modulated by small molecules [38, 47, 102]. Treatment
of cells with the m7G cap analogue (m7GpppG) leads to
disruption of eIF4E nuclear bodies and re-distribution of
eIF4E to the cytoplasm [47, 102]. Treatment with a physical
mimic of the m7G cap, ribavirin, has a similar eﬀect where it
leads to an increased fraction of eIF4E in the cytoplasm [38].
Consistently, ribavirin treatment leads to reduction in eIF4E
dependent mRNA export. Note that ribavirin or m7GpppG,
under these conditions, does not alter the levels of eIF4E
[38, 47, 102].
In summary, factors such as 4E-T that so drastically
aﬀect the subcellular localization of eIF4E, are positioned
to aﬀect eIF4E’s physiological activities in proliferation and
oncogenic transformation (Figure 2). In addition, given that
eIF4E modulates the expression of some transcripts only at
onelevel(suchascyclinD1attheexportlevelorVEGFatthe
translation level), modulation of its subcellular distribution
is likely to lead to diﬀerential eﬀects on eIF4E sensitive
transcripts. In this way, these eIF4E traﬃckers could mod-
u l a t eg e n ee x p r e s s i o nd i ﬀerentially favouring/disfavouring
subsets of genes (e.g., export versus translation) and thereby6 Journal of Oncology
modulate the biological eﬀects of eIF4E. This level of
modulation would allow a more tailored response to cellular
stresses and stimuli.
7.How Does eIF4EBecome ElevatedinCancer?
Given that elevated eIF4E levels are found in many human
cancers and are associated with poor prognosis [28, 30,
43, 103], it is critical to understand how eIF4E levels
become elevated. There are likely multiple mechanisms that
could account for elevated eIF4E mRNA levels in these
primary patient specimens, for example, gene ampliﬁcation,
transcriptional dysregulation, and alterations in mRNA
stability. In fact, elevated eIF4E levels may result from
any combination of these. For instance, eIF4E levels are
elevated, at least in part, in breast cancer and head and neck
squamous cell carcinomas due to ampliﬁcation of the eIF4E
gene [13, 104, 105]. Studies in cell culture indicate that the
eIF4E promoter contains an E-box, and that its expression
is regulated by c-myc [5, 6, 64]. Interestingly, c-myc is a
downstream mRNA export and mRNA translation target
of eIF4E which suggests existence of a potential feedback
loop [106, 107]. As eIF4E is made in c-myc null mice,
there must be other means by which it is induced [37].
Further, eIF4E mRNA levels are substantially reduced in
primary leukemia specimens transduced with the IκB-SR
[3, 108]. In addition, some studies have found increased
eIF4E expression during hypoxic conditions by IHC analysis
of conﬁned breast cancer biopsies [50]. In this way, the
hypoxia that accompanies tumor growth may stimulate
eIF4E expression.
Another mechanism that appears to be involved in the
elevation of eIF4E in HNSCC is HuR dependent stabilization
ofeIF4Etranscripts.Speciﬁcally,inFaDucells,bothHuRand
eIF4E levels are elevated relative to control cells. Here, the
mRNA stability factor, HuR, associates with eIF4E mRNA
and enhances its stability [109]. HuR is a member of a
family of proteins which modulate the stability of mRNAs
by associating with U or AU rich elements (denoted AREs)
typically in the 3 UTR of these messages [109]. Hu/ELAV
family members are primarily neuronal with the exception
of HuR, which is ubiquitously expressed. HuR modulates
the expression of many proliferative mRNAs which contain
AREs including (but not limited to): cyclin D1, cyclin B1,
c-myc, VEGF, and so forth [109, 110]. Interestingly, many
of these target mRNAs are also export and /or translational
targets of eIF4E (e.g., all of the ones listed above). HuR
has been implicated in oncogenesis. Its overexpression is
correlated with the formation of tumors in mouse xenograft
models [111, 112]. Microarray data of normal and cancer
tissues indicated that HuR is elevated in human breast
and lung cancer [96, 113, 114]. Further, HuR promotes
angiogenesis, as does eIF4E [37]. The overlap in mRNA
targets coupled to the fact that both eIF4E and HuR are
involved in transformation and elevated in human cancers,
suggests that eIF4E could be a downstream eﬀector of HuR
activity. Thus HuR is positioned to modulate the eIF4E
regulon by both altering its expression and the expression
of eIF4E’s downstream eﬀectors. Future studies that monitor
HuR levels in HNSCC could be very interesting and may
suggest HuR as another prognostic marker.
8.Targeting eIF4EinHNSCC- from
Cellsto Patients
To date, targeting of eIF4E in HNSCC remains in the
preclinical stage. Three main pre-clinical strategies have
been described: knockdown of eIF4E levels through the use
of antisense oligonucleotides or RNA interference, suicide
gene therapy, hormone analog—4EBP fusion peptide, and
targeting eIF4E activity with ribavirin.
Inhibition of eIF4E using antisense oligonucleotides
t oe I F 4 Ew a sﬁ r s tp e r f o r m e di nH e L ac e l l sa n dR a s -
transformed mouse ﬁbroblasts, and resulted in the reversal
of the malignant phenotype [115–117]. Decreasing levels of
eIF4E in the human breast cancer cell line MDA-MB-435
and human prostate cancer cell line PC-3 diminished their
angiogenic and tumorogenic properties [33, 39]. The ﬁrst
laboratory to ﬁnd eIF4E levels elevated in both breast and
HNSCC, the De Benedetti lab, was also the ﬁrst to target
eIF4E in HNSCC cells [33, 49]. Using antisense RNA to
eIF4E,theydemonstratedthattheyloweredbotheIF4Elevels
and the levels of its downstream targets, VEGF and FGF-
2. FaDu cells treated with antisense oligonucleotides also
show reduced oncogenic properties of these cells including
displaying increased contact inhibition, reduced growth in
soft agar, and reduced tumorigenicity in xenograft mouse
models [49]. A related strategy used small interfering RNAs
targeting eIF4E either alone or in combination with cis-
platin in the UMSCC22B HNSCC cell line [118]. As
expected, siRNA to eIF4E lowered eIF4E levels and reduced
the oncogenicity of this cell line. The addition of cis-platin
increased the eﬀects of the knockdown of eIF4E alone.
This same strategy, combining siRNA to eIF4E with cis-
platin, was also used in breast carcinoma cells with success
[119].
Antisense oligonucleotides (ASOs) were also used by
the Graﬀ lab in a human prostate cancer xenograft mouse
model [39]. Here, mice that intravenously received anti-
sense oligonucleotides showed signiﬁcant reduction of eIF4E
expression and suppressed tumor growth. No toxicity was
observed. The ASOs used also target murine eIF4E, leading
to an 80% reduction of eIF4E in mouse liver; however
there was no aﬀect on body weight, organ weight, or liver
transaminase levels. Eli Lilly is currently pursuing clinical
trials using this strategy.
Suicide gene therapy is a method of introducing a gene,
the expression of which will make a tumor cell uniquely
susceptible to attack and destruction [120]. This strategy
utilizes delivery of herpes simplex virus-thymidine kinase
(HSV-Tk) by nonreplicative adenovirus vectors to the cells
and subsequent ganciclovir (GCV) treatment [121, 122].
The HSV-Tk has the ability to phosphorylate and activate
prodrug GCV to its cytotoxic triphosphate form with 1000-
fold higher eﬃciency than its mammalian homologues.
As a consequence, cells transfected with HSV-Tk can beJournal of Oncology 7
targeted for death by treatment with ganciclovir, while
normal cells would remain mainly unaﬀected [121, 122].
Although this strategy gained wide popularity as potential
treatment for HNSCC, this strategy had two principal
challenges: acceptable cytotoxic speciﬁcity to tumor cell
targets and adequate delivery of the suicide gene. In order to
speciﬁcally target eIF4E overexpressing cells, a long 5 UTR
(from FGF-2) was fused to the thymidine kinase gene
(5 UTR-Tk) to preferentially sensitize expression of this gene
to eIF4E levels [123, 124]. This system was reported highly
eﬃc i e n ti nab r o a ds p e c t r u mo fb r e a s tc a n c e rc e l ll i n e s
[124]. Using a mouse minimal residual disease soft-tissue
metastasis model for HNSCC, the Li group examined the
eﬃcacy of this strategy to target solid tumors cells that
are overexpressing eIF4E [123]. In this study, mice that
received Ad-HSV- 5 UTR-Tk fusion and GCV treatment
showed longer disease free survival than the control group
[123].
In order to inhibit eIF4E in ovarian cancers, Ko et
al. [125] designed 4EBP-based peptide fused to an analog
of gonadotropin-releasing hormone (GnRH) to speciﬁcally
target ovarian and other endocrine cancer cells, that are
widely overexpressing the GnRH receptor. This fusion
peptide inhibited growth of the GnRH receptor expressing
tumor cells and showed potent antitumor eﬀect in a
mouse xenograft model of epithelial ovarian cancer, without
signiﬁcant cytotoxic eﬀects in other tissue.
9.SuccessfulTargetingof eIF4EintheClinic
To date, eIF4E has been successfully targeted only in a par-
ticularly aggressive form of acute myeloid leukemia French
American British (FAB) subtype M4/M5 AML. These poor-
prognosis leukemias are characterized by elevated eIF4E
levels [37]. In these studies, ribavirin, a competitive inhibitor
ofthenaturalligandofeIF4Ethem7Gcap,wasusedtotarget
its biochemical and oncogenic activities [38]. In a phase
II proof-of-principle clinical trial of refractory, relapsed
or patients who cannot undergo induction chemotherapy
were treated with ribavirin [126]. eIF4E inhibition led to
striking clinical improvement including complete remis-
sion, partial remission, and blast response. Ribavirin was
originally used as an antiviral drug and was well tolerated
with no therapy related toxicities observed. Note that in
these studies, ribavirin was the only cytotoxic chemotherapy
permitted.
Clinical response correlated with inhibition of eIF4E
activity and redistribution of the eIF4E protein from the
nucleus to the cytoplasm [126]. In these AML patients,
eIF4E was both highly upregulated and found mainly in
the nucleus [38, 82]. The mRNA export activity of eIF4E
is also upregulated in these specimens [37, 126]. After
28 days of treatment with ribavirin, eIF4E was markedly
re-distributed from the nucleus to the cytoplasm [126].
Surprisingly, eIF4E protein levels were also downregulated,
which is the ﬁrst time this downregulation has been
reported postribavirin treatment (note that in the previous
experiments, ribavirin treatment was followed in cell culture
for up to 48 hours, not 28 days as used for patients
[127–130]). It is possible that this downregulation occurs
via a negative feedback loop due to prolonged inhibition
of eIF4E. Alternatively, decreased eIF4E levels could be a
result of diﬀerential sensitivity within a heterogeneous cell
population to ribavirin. At the same time, the production
of eIF4E mRNA export targets such as cyclin D1 and NBS1
mRNA is repressed in patients. Further, eIF4E dependent
Akt activation is reduced, which is consistent with its
requirement for NBS1.
Durability of clinical response is key to success. In the
treatment of M4 and M5 AML, a regimen of chemotherapy
typically combines Ara-C with danurubicin or idarubicin
[127–130]. This regimen, named 7+3, induces remission
in most patients. However, in the absence of consolidation
therapy (typically with Ara-C), remissions only last 2–4
months [127–130]. Like many targeted monotherapies such
as ATRA in APL or ﬂt3 inhibitors in AML [131–134],
after 2–4 months of ribavirin treatment, development of
drug resistance was observed [126]. In these cases, although
eIF4E levels remain low, eIF4E relocalizes to the nucleus,
which generally correlated with relapse of the disease. The
molecular events underpinning the return of eIF4E to the
nucleus are not known, but clearly these events play a critical
role in the response of these cells to ribavirin. To try to
overcome resistance, ribavirin will be combined with other
chemotherapy regimens. Although these studies are in AML
patients, the ability to target eIF4E has clear implications for
thedevelopmentoftreatmentsforHNSCCandothercancers
with elevated eIF4E.
10. From Leukemia to HNSCC
Several previous studies indicate that ribavirin is an eﬀective
inhibitor of growth in FaDu cells [38, 82]. In xenograft
mouse models, studies had shown that genetically reducing
the levels of eIF4E protein by antisense RNA substantially
impaired tumour growth [39, 119]. Similarly, addition of
oralribavirintomiceafterFaDuxenograftledtosigniﬁcantly
smaller tumours than for control animals [38]. Further,
ribavirin inhibited anchorage dependent growth in FaDu
cells in culture and signiﬁcantly reduced levels of cyclin
D1 and NBS1 proteins, and decreased Akt activation [82].
These ﬁndings in cell culture as well as results from
treatment of AML patients suggest that targeting eIF4E
with ribavirin in HNSCC may yield promising clinical
results.
11. Conclusions
In this paper, we have described the biochemical function
and biological eﬀects of eIF4E. We summarize the roles
and regulation of eIF4E in gene expression (Figure 2). We
discussed the dysregulation of eIF4E in multiple cancers
and the current strategies being considered to target its
activity. eIF4E is an indicator of poor prognosis in HNSCC
and hopefully, therapeutic approaches targeting eIF4E will
beneﬁt these patients.8 Journal of Oncology
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